Avis Budget (CAR) Stock

AMONG THE MOST IMPORTANT SPORTS RACING CARS OF ALL TIME | D-TYPE OFFERED WITHOUT RESERVE, ESTIMATED TO BRING $6.5-8.5M AT MARCH 7-8 AUCTION AMONG THE MOST IMPORTANT SPORTS RACING CARS OF ALL TIME | D-TYPE OFFERED WITHOUT RESERVE, ESTIMATED TO BRING $6.5-8.5M AT MARCH 7-8 AUCTION

SHANGHAI , Jan. 20, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that KJ-C2320, an allogeneic CAR T-cell therapy targeting CD38, has administered the first dose to a patient in an investigator-initiated trial (IIT). KJ-C2320 is developed based on CARsgen's THANK-uCAR® platform.

SOUTH SAN FRANCISCO, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today announced pipeline updates, including its plans to advance IMPT-314, a potentially best-in-class therapy for aggressive large B-cell lymphoma, into pivotal trials. IMPT-314 is an autologous dual-targeting CD19/CD20 chimeric antigen receptor (CAR) T-cell product candidate designed to increase complete response rates and prolong the duration of the responses as compared to the approved CD19‑targeted CAR therapies for the treatment of large B-cell lymphoma.

Lille, le 3 janvier 2025 Avis de mise à disposition  du bilan semestriel 2024 du contrat de liquidité du Crédit Agricole Nord de France La Caisse régionale du Crédit Agricole Nord de France annonce avoir mis à disposition du public et déposé auprès de l'Autorité des Marchés Financiers son bilan semestriel du contrat de liquidité contracté avec Oddo Corporate Finance. Le bilan semestriel 2024 du contrat de liquidité peut être consulté sur le site de présentation du Crédit Agricole Nord de France à l'adresse http://communication.ca-norddefrance.fr/ rubrique Publications.

SHANGHAI , Dec. 31, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces the initiation of an investigator-initiated trial (IIT) in China for KJ-C2219, an allogeneic CAR T-cell therapy, targeting CD19/CD20. The trial will evaluate KJ-C2219 for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL).

SHANGHAI , Dec. 30, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces the positive results from the pivotal Phase II clinical trial CT041-ST-01(NCT04581473). This study is an open-label, multicenter clinical trial evaluating the safety and efficacy of satricabtagene autoleucel ("satri-cel", CT041) (an autologous CAR T-cell product candidate against Claudin18.2) in subjects with Claudin18.2 expression-positive, advanced gastric/gastroesophageal junction cancers that have failed at least 2 prior lines therapy.

CAR benefits from strong demand, fleet management and technology investments, which boost profitability. However, lack of dividends and low liquidity pose risks.

Strategic financing supports clinical advancement in Phase 1 APOLLO study investigating MT-601 in patients with lymphoma who relapsed after anti-CD19 CAR-T cells Strategic financing supports clinical advancement in Phase 1 APOLLO study investigating MT-601 in patients with lymphoma who relapsed after anti-CD19 CAR-T cells

Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF). the UK-listed biopharmaceutical company focused on treatments for blood cancers, has entered a collaboration with Kure.ai to develop an ultrafast manufacturing process for its CAR-T cell therapies.